Session: SUN 839-872-Diabetes & Obesity Management
Poster Board SUN-851
“Religious Fasting in patients with Type 2 Diabetes Mellitus Using Sitagliptin/Metformin-based therapy”
M. Al-Sayed, MD, M. Joudeh
Background: Management of patients with Type 2 Diabetes Mellitus during the fasting month of Ramadan, has been a big challenge in terms of control and avoiding of complications; and there has been very few studies evaluating Sitagliptin/Metformin-based therapy in the treatment of these patients.
Objective: To study the effect of religious fasting on hypoglycemic episodes, glycemic control and ophthalmic changes in patients with type 2 Diabetes Mellitus using a Sitagliptin-Metformin- based therapy.
Methods: 15 Patients (8 Males, 7 Females) with type 2 Diabetes who were mainly managed with oral hypoglycemic agents, prospectively completed this one-lunar month study. The duration of fasting averaged 16 hours/day. Patients received a Sitagliptin/Metformin-based therapy. Long-acting Sulfonylurea (7 patients) agents or pioglitazone (2 patients) were added if blood glucose was not controlled. Twice a day blood glucose measurements were done using a glucometer (2 hours before, and 2 hours after food), Baseline lab included kidney and liver function tests, HgA1C, and fasting glucose. Ophthalmic exam was done by an ophthalmologist. All the baseline lab and the ophthalmic exam were repeated at the end of the study.
Results: In all patients, there were no hypoglycemic episodes requiring breaking the fast. There was a non-significant decrease in Glycosylated Hemoglobin (7.68 to 7 ). All patients showed no change in eye exam, except for one patient who showed an improvement. Kidney and liver function testes stayed within normal limits throughout the study.
Conclusions: In patients with Type 2 Diabetes Mellitus, a Sitagliptin/Metformin-based therapy during the fasting month of Ramadan was an effective and safe treatment for such patients. This study is mainly limited by the small cohort. This pilot study necessitates future and larger studies.
Nothing to Disclose: MYA
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters